|
|
||||||||



,
* The Wistar Institute, Philadelphia, PA 19104;
Infectious Diseases Division, University of Pennsylvania, Philadelphia, PA 19104;
Molecular and Functional Genomics Department, Sanofi-Synthelabo Recherche, Labege, France; and
Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, PA 19107
We show in this study that acute exposure of PBMCs derived from HIV-infected subjects to IL-13 results in increased recall T cell lymphoproliferative responses against HIV-1 p24 (n = 30, p < 0.0001) and other recall Ags (influenza, n = 43, p < 0.0001; purified protein derivative tuberculin, n = 6, p = 0.0299). This effect is due to a mechanism that acutely targets APC function in the adherent monocyte subset, as shown by the expansion of CD4+ T cell responses following coculture of IL-13-treated enriched CD14+ monocytes with donor-matched enriched CD4+ T cells and Ag. Exposure to IL-13 over 1872 h resulted in a significant enhancement of monocyte endocytosis (n = 11, p = 0.0005), CD86 expression (n = 12, p = 0.001), and a significant decrease in spontaneous apoptosis (n = 8, p = 0.008). Moreover, IL-13 exposure induced a significant decrease of significantly elevated constitutive levels of PBMC-secreted TNF-
(n = 14, p < 0.001) and IL-10 (n = 29, p < 0.001) within 18 h of exposure ex vivo, also reflected by decreased gene expression in the adherent cell population. Our data show that IL-13 is able to acutely enhance the function of the CD14+ cell subset toward supporting Ag-specific cell-mediated responses in chronic HIV-1 infection.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |